UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lead Optimization of a Novel Series of Imidazo[1,2‑a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

Journal of medicinal chemistry, 2014-06, Vol.57 (12), p.5293-5305

2014

Volltextzugriff (PDF)

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A742-A742

2023

Volltextzugriff (PDF)

645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A738-A738

2023

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

Antimicrobial agents and chemotherapy, 2022-01, Vol.66 (1), p.e0143621

2022

Volltextzugriff (PDF)

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

Cancers, 2022-10, Vol.14 (19), p.4821

2022

Volltextzugriff (PDF)

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Nature Medicine, 2013-09, Vol.19 (9), p.1157-1160

2013

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial

Antimicrobial agents and chemotherapy, 2023-01, Vol.67 (1), p.e0112322

2023

Volltextzugriff (PDF)

Abstract 4974: Q702, selective Axl/Mer/CSF1R triple kinase inhibitor enhance the activity of immune checkpoint inhibitor by alteration of immunosuppressive tumor microenvironment

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4974-4974

2020

Volltextzugriff (PDF)

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2673-TPS2673

2021

Volltextzugriff (PDF)

Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay

European journal of medicinal chemistry, 2021-01, Vol.209, p.112550, Article 112550

2021

Volltextzugriff (PDF)

Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4139-4139

2019

Volltextzugriff (PDF)

Abstract A205: Q701, a selective Axl and Mer inhibitor as an immune checkpoint inhibitor

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A205-A205

2018

Volltextzugriff (PDF)

Abstract B162: Highly selective, orally available CDK7 inhibitor for cancer therapy

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B162-B162

2018

Volltextzugriff (PDF)

Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2255-2255

2023

Volltextzugriff (PDF)

Multivalent Nanosheet Antibody Mimics for Selective Microbial Recognition and Inactivation

Advanced materials (Weinheim), 2021-06, Vol.33 (22), p.e2101376-n/a

2021

Volltextzugriff (PDF)

Transition-Metal Dichalcogenide Artificial Antibodies with Multivalent Polymeric Recognition Phases for Rapid Detection and Inactivation of Pathogens

Journal of the American Chemical Society, 2021-09, Vol.143 (36), p.14635-14645

2021

Volltextzugriff (PDF)

Antibacterial Strategies: Multivalent Nanosheet Antibody Mimics for Selective Microbial Recognition and Inactivation (Adv. Mater. 22/2021)

Advanced materials (Weinheim), 2021-06, Vol.33 (22), p.n/a

2021

Volltextzugriff (PDF)

Modulation of the Vault Protein-Protein Interaction for Tuning of Molecular Release

Scientific reports, 2017-11, Vol.7 (1), p.14816-10, Article 14816

2017

Volltextzugriff (PDF)

Multi-die chip on wafer thermo-compression bonding using non-conductive film

2015 IEEE 65th Electronic Components and Technology Conference (ECTC), 2015, p.17-21

2015

Volltextzugriff (PDF)

Wafer Level Multi-chip Gang Bonding Using TCNCF

2016 IEEE 66th Electronic Components and Technology Conference (ECTC), 2016, p.122-127

2016

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(18)
Tagungsberichte
(2)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lead Optimization of a Novel Series of Imidazo[1,2‑a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors

Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial

Abstract 4974: Q702, selective Axl/Mer/CSF1R triple kinase inhibitor enhance the activity of immune checkpoint inhibitor by alteration of immunosuppressive tumor microenvironment

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay

Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy

Abstract A205: Q701, a selective Axl and Mer inhibitor as an immune checkpoint inhibitor

Abstract B162: Highly selective, orally available CDK7 inhibitor for cancer therapy

Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

Multivalent Nanosheet Antibody Mimics for Selective Microbial Recognition and Inactivation

Transition-Metal Dichalcogenide Artificial Antibodies with Multivalent Polymeric Recognition Phases for Rapid Detection and Inactivation of Pathogens

Antibacterial Strategies: Multivalent Nanosheet Antibody Mimics for Selective Microbial Recognition and Inactivation (Adv. Mater. 22/2021)

Modulation of the Vault Protein-Protein Interaction for Tuning of Molecular Release

Multi-die chip on wafer thermo-compression bonding using non-conductive film

Wafer Level Multi-chip Gang Bonding Using TCNCF

Suchergebnisse filtern